...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AGM Sept. 12, 2018

I am thinking that they are going to need shareholder approval for something. It could be for any one of the topics that have been up for discussion here lately. Don did say something about the possibility of a Zenith sale a while ago, that fits into this time line. JMHO.

Share
New Message
Please login to post a reply